louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06787833: The Effect of Classical Music on Dental Students' Stress and Anxiety During the COVID-19 Pandemic
Official title: The Effect of Performing Clinical Practice with Classical Music on Dental Students' Stress and Anxiety During the COVID-19 Pandemic
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Psychological Factors
Keywords: Beethoven
Coronavirus anxiety
Music
Mozart
Perceived stress
Lead sponsor: Karabuk University
Sponsor class: OTHER
Collaborators: name: Ankara University
First posted: 2025-01-22
Enrollment: 46
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The students adapted to the environment for the first 2 days, were informed about the study, and their informed consent was obtained. Participants were asked to answer all questions and to give a single answer to each question. The students filled in the questionnaire form used in the study without any intervention by the researcher. Participants filled out the same survey four times at different times following a specific protocol.

Detailed description: The study was conducted with a specific protocol. First, they were asked to complete a questionnaire including socio-demographic data, Perceived Stress Scale (PSS-14), and Coronavirus Anxiety Scale (CAS) before patient admission (T1). The students were asked to complete the same questionnaire at the end of the day after working for 2 days (T2) and in the morning on the 5th day of their study before seeing patients (T3). Each of the students participating in the study was given disposable headphones every day during the week of music listening. In this study, Beethoven's Moonlight Sonata (1 hour 2 minutes) Mozart's Serenata Notturna KV239 (12.50 minutes) and Pachelbel's Canon in D major (6.16 minutes)were used. It was shared with the students via WhatsApp and they were allowed to listen to this music on their phones for 1 week (2 hours on average) during the study period. The same questionnaire was refilled at the end of the week in which music was played (T4).

Eligibility criteria: Inclusion Criteria:

* Aged 20 years and over,
* Systemically healthy and drug-free,
* Students who were obliged to practice in the clinic of the Department of Periodontology, Faculty of Dentistry, Ankara University, within the scope of the education program

Exclusion Criteria:

* Systemic diseases
* Medication use

Primary outcomes:
measure: Participants' initial stress and anxiety levels
timeFrame: up to 2 days
Secondary outcomes:
measure: Participants' stress and anxiety levels after listening to music
timeFrame: up to 2 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: AnkaraUniversity
city: Karabük
country: Turkey
facility: Karabuk University
Study officials:
References:
citation: Groarke JM, Hogan MJ. Listening to self-chosen music regulates induced negative affect for both younger and older adults. PLoS One. 2019 Jun 6;14(6):e0218017. doi: 10.1371/journal.pone.0218017. eCollection 2019.
Clinical trial NCT02890433: Standard Precautions Versus Contact Additional Precautions Against Multi-drug Resistant Bacteria in Intensive Care Unit (PSBMR)
Official title: Are Standard Precautions as Efficient as Contact Additional Precautions Against the Transmission of Multi-drug Resistant Bacteria in Intensive Care Unit ?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multi-drug Resistant Bacteria
Lead sponsor: Centre Hospitalier Régional Metz-Thionville
Sponsor class: OTHER
First posted: 2016-09-07
Enrollment: 3124
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients hospitalized in the resuscitation unit of the study

Brief summary: The national recommendations promote the applying of the Contact Additional Precautions (CAP) with the Standard Precautions (SP) to limit the transmission of multi-drug resistant (MDR) bacteria. However, that could entail more costs and a reduction of quality of the patient care.

Detailed description: The national recommendations promote the applying of the Contact Additional Precautions (CAP) with the Standard Precautions (SP) to limit the transmission of multi-drug resistant (MDR) bacteria. However, that could entail more costs and a reduction of quality of the patient care.

This study seeks showing it in way of a non-interventional research in a resuscitation unit. Two periods are compared for noticing the rates of MDR bacteria contaminations.

Eligibility criteria: Inclusion Criteria:

* hospitalization in resuscitation unit

Exclusion Criteria:

* opposition for gathering data

Primary outcomes:
measure: Rate of Meticillin Resistant Staphylococcus Aureus (MRSA) and Enterobacteriaceae producing Extended Spectrum Beta-Lactamase (EESBL) per 1000 hospitalization days
timeFrame: 1000 days
Secondary outcomes:
Other outcomes:
Locations:
city: Metz Cedex 03
country: France
facility: CHR Metz-Thionville
Study officials:
affiliation: CHR Metz-Thionville
name: Jocelyne SELLIES, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03734133: Electromyography Evaluation of the Impacts of Different Insoles in the Activity Patterns of the Lower Limb Muscles
Official title: Electromyography Evaluation of the Impacts of Different Insoles in the Activity Patterns of the Lower Limb Muscles: A Cross-over Quasi-experimental Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Electromyography
Muscles
Foot Orthoses
Lead sponsor: Universidad de León
Sponsor class: OTHER
First posted: 2018-11-07
Enrollment: 9
Sex: ALL
Minimum age (years): 14
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main objective of this research is to demonstrate that the use of insoles of different hardness in motorcycle riders may cause variations in the electromyographic activity of the lower limb muscles during the race. This study is a cross-over quasi-experimental study. Nine motorcycle riders were recruited. Electromyographic activity of the lower limb muscles is recorded under different insole types.


Eligibility criteria: Inclusion Criteria:

* Healthy subjects
* Motorcycle riders

Exclusion Criteria:

* Musculoskeletal conditions
* Neurological alterations
* Systemic diseases.

Primary outcomes:
measure: Superficial electromyography peak measured as percentage
timeFrame: Change from Baseline superficial electromyography peak at 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Universidad complutense de Madrid
Study officials:
References:
Clinical trial NCT00768833: Study Evaluating the Nasopharyngeal Carriage in Healthy Children
Official title: Nasopharyngeal Carriage in Children After Introduction of General Pneumococcal Immunization in Germany
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Subjects
Keywords: S.pneumoniae healthy subjects
Healthy subjects
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-10-08
Enrollment: 242
Sex: ALL
Minimum age (years): 3
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: The purpose of this study is to assess the prevalence of pneumococcal stereotypes in the nasopharynx of healthy children and to describe the changes of nasopharyngeal carriage at different ages over time.


Eligibility criteria: Inclusion Criteria:

Main inclusion criteria:

* Age at enrolment 3 to 4 month Main

Exclusion Criteria:

* Malformation or injury of the nasopharynx
* Known or suspected immunodeficiency
* Relevant immunosuppression
* Use of antibiotics up to 10 days prior to study inclusion

Primary outcomes:
measure: Number and frequency of S. pneumonia positive serotypes
timeFrame: 57 months
Secondary outcomes:
measure: Changes in number and frequency of S. pneumonia positive children at different ages over time
timeFrame: 57 month
Other outcomes:
Locations:
city: Offenbach
country: Germany
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT04859933: AV Node Isolation in Atrial Fibrillation vs. Modulation by "Pace and Ablate" Strategy
Official title: AV Node Isolation in Atrial Fibrillation vs. Modulation by "Pace and Ablate" Strategy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
AV Node Ablation
Escape; Rhythm
Lead sponsor: Heart and Diabetes Center North-Rhine Westfalia
Sponsor class: OTHER
First posted: 2021-04-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to Heart- and Diabetes Centre NRW for AV-node ablation/isolation.

Brief summary: AV-node ablation (AVNA) is a common therapy option for rate control strategy of permanent atrial fibrillation with numerous side effects. The investigators hypothesised that an isolation of the AV node is concomitant with less occurrence of new bundle brunch blocks, more frequent preservation and higher rate of escape rhythm compared to AVNA. This retrospective study includes 20 patients being treated with AV-node isolation (AVNI) and 40 historical AVNA-controls. Among others these two methods were compared regarding escape rhythm, delta QRS, procedure time, ablation points, fluoroscopy time and total dose area product (DAP).


Eligibility criteria: Inclusion Criteria:

* paroxysmal, persistend or permanent atrial fibrillation; indication for AVNA

Exclusion Criteria:

* other indications for AVNA than atrial fibrillation as AVNRT, atrial flutter, atrial tachycardia

Primary outcomes:
measure: AV-node escape rhythm
timeFrame: intraoperative, follow-up after 1 to 3 month
measure: bundle branch blocks
timeFrame: intraoperative, follow-up after 1 to 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Bad Oeynhausen
country: Germany
facility: Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum
Study officials:
References:
Clinical trial NCT05408533: Silver-Coated vs Standard Catheter for UTI Prevention
Official title: Silver-coated Catheter Versus Standard Catheter for UTI Prevention in a Short-term Transurethral Indwelling Catheter Population After Pelvic Reconstructive Surgery: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: UTI
Keywords: Silver-coated catheter
UTI
Pelvic Reconstructive Surgery
Urogynecology
Lead sponsor: TriHealth Inc.
Sponsor class: OTHER
First posted: 2022-06-07
Enrollment: 310
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Primary Aim: To determine whether silver-coated transurethral catheter decreases the incidence of culture-confirmed urinary tract infection for women with catheter-managed urinary retention after pelvic reconstructive surgery

Secondary Aims:

To assess difference in bacterial uropathogens isolated in urine cultures Adverse symptoms possibly caused by silver-coated catheter


Eligibility criteria: Inclusion Criteria:

* Patients who undergo major or minor pelvic organ prolapse surgery of any compartment, or urinary incontinence surgery that are diagnosed with POUR via failed retrograde voiding trial and require an indwelling transurethral catheter upon hospital discharge. Sacral neuromodulation procedures and intradetrusor onabotulinumtoxinA (Botox) injections are excluded.

Exclusion Criteria:

* Unwilling or unable to participate in the study.
* Unwilling or unable to do a catheter self-removal at home.
* Inability to understand English.
* Pregnant women
* Patient personal history of urogenital anomaly, neurogenic bladder, use of chronic self-intermittent catheterization or suprapubic tubes, ureteral stents or other genitourinary indwelling devices, immunosuppressed state or chronic use of steroids.
* Currently (prior 3 months) undergoing medical management for recurrent UTI or interstitial cystitis
* Active urinary tract infection.
* Intraoperative bladder injury or cystotomy
* Physical or mental impairment that would affect the subject's ability to perceive urinary tract infection symptoms
* Reported allergy to silver metal

Primary outcomes:
measure: Incidence of UTIs requiring treatment
timeFrame: approximately 4 weeks
Secondary outcomes:
measure: Assess the types of bacterial uropathogens isolated from the urine cultures
timeFrame: approximately 4 weeks
measure: Adverse symptoms possibly causes by silver-coated catheter
timeFrame: approximately 4 weeks
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Cincinnati Urogynecology Associates
state: Ohio
city: Cincinnati
country: United States
facility: Good Samaritan Hospital
state: Ohio
Study officials:
affiliation: TriHealth Inc.
name: Jennifer Yeung, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01117233: Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429
Official title: A Randomised, Placebo Controlled, Double-Blind, Third Party Open, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Healthy volunteers
PK
PD
safety and toleration
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-05-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose is to study the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04427429 administered intravenously to healthy adult volunteers


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects between the ages of 18 and 50 years inclusive (unless local regulations dictate a minimum age of 21 years). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight of between 50 kg and 100 kg inclusive.
* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial.

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, genitourinary, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, symptomatic, seasonal allergies at time of dosing).
* Any condition possibly affecting drug absorption.
* 12-lead ECG demonstrating QTcF \>450 msec at Screening. If QTcF exceeds 450 msec, the ECG should be repeated two more times and the average of the three QTcF values should be used to determine the subject's eligibility.

Primary outcomes:
measure: Adverse events, Vitals, ECG, laboratory safety tests, IV infusion site reaction
timeFrame: up to 84 days
measure: Plasma pharmacokinetics of PF-04427429
timeFrame: up to 84 days
Secondary outcomes:
measure: Free and total CGRP plasma concentrations
timeFrame: up to 84 days
measure: anti-drug antibody
timeFrame: up to 84 days
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00961233: Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)
Official title: Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE): Esophageal Medication Distribution, Treatment Response, and Effect on the Adrenal Axis.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Eosinophilic Esophagitis
Keywords: eosinophilic esophagitis
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2009-08-18
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to conduct a clinical trial of two formulations of budesonide (nebulized/swallowed versus viscous/swallowed) in patients with EoE to determine if medication contact time and distribution in the esophagus relates to treatment response. The investigators will also determine if there is systemic absorption of these topical steroids. The investigators hypothesize that tissue and symptom response will correlate with esophageal medication contact time and distribution, and that significant systemic absorption will not be seen.


Eligibility criteria: Inclusion Criteria:

* New diagnosis of eosinophilic esophagitis (per 2007 consensus guidelines)

Exclusion Criteria:

* Age \< 18
* Inability to read or understand English
* Pregnant or nursing women
* Previous allergic reactions to steroid medications
* Current use of systemic steroids

Primary outcomes:
measure: Tissue Eosinophil Counts
timeFrame: 8 weeks
Secondary outcomes:
measure: Adrenal Insufficiency
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: University of North Carolina
state: North Carolina
Study officials:
affiliation: University of North Carolina, Chapel Hill
name: Evan S Dellon, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM, Ivanovic M, Chau A, Woosley JT, Madanick RD, Orlando RC, Shaheen NJ. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology. 2012 Aug;143(2):321-4.e1. doi: 10.1053/j.gastro.2012.04.049. Epub 2012 May 3.
Clinical trial NCT06838533: Patient Specific PEEK Versus Titanium Patient Specific Plates in The Fixation of Computer-Guided Advancement Genioplasty
Official title: Patient Specific Polyetheretherketone (PEEK) Miniplates Versus Titanium Genioplasty Plates in The Fixation of Computer-Guided Advancement Genioplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mandible; Deformity
Keywords: Genioplasty
PEEK
Mandible deformity
Lead sponsor: Faculty of Dental Medicine for Girls
Sponsor class: OTHER_GOV
First posted: 2025-02-20
Enrollment: 14
Sex: ALL
Minimum age (years): 17
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of polyetheretherketone (PEEK) versus titanium patient specific plates in the fixation of computer-guided advancement genioplasty.

Detailed description: Aim: Comparison between polyetheretherketone (PEEK) and titanium patient specific plates in the fixation of computer-guided advancement genioplasty.

Patients and Methods: This study included fourteen patients indicated for advancement genioplasty. Patients were assigned randomly into one of two equal groups. Group A (Control group) included seven patients who were treated by computer guided advancement genioplasty using patient specific titanium plates and Group B(Study group) involved seven patients who were treated by computer guided advancement genioplasty using patient specific PEEK plates.

Eligibility criteria: Inclusion Criteria:

* Patients who are indicated to advancement genioplasty.
* Patients with completed growth.
* Physically and psychologically able to tolerate surgical procedures.

Exclusion Criteria:

* Presence of any medical conditions that contraindicate the surgical procedure.
* Any medical condition that compromises the healing and surgical outcome.

Primary outcomes:
measure: Stability of PEEK vs Titanium plates
timeFrame: 6 months follow up
Secondary outcomes:
measure: Patient satisfaction
timeFrame: 6 months
measure: Cost of patient specific plated (PEEK and titanium)
timeFrame: 6 months
measure: Soft tissue healing
timeFrame: 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Dina mohamed abdelwahab
Study officials:
affiliation: Assistant professor at faaculty of dentistry AlAzhar university
name: Nahed Adly, consultant
role: STUDY_DIRECTOR
References:
Clinical trial NCT04403633: A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention
Official title: Improving Patient-Centered Care in Pediatric Acute Kidney Injury (Change Peds AKI)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Acute Kidney Injury
Keywords: AKI
Pediatric AKI
Acute Kidney Injury
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2020-05-27
Enrollment: 25
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to improve patient-centered care for acute kidney injury (AKI) in order to decrease the adverse health outcomes associated with this common condition.

Detailed description: There is a need to provide better patient-centered care for acute kidney injury (AKI) in order to improve the adverse health outcomes associated with this common condition. This project involves thorough evaluation of patient and provider feedback on barriers and facilitators to pediatric AKI self-management in order to develop patient-centered pediatric AKI interventions. This will be done through interviews with families of patients diagnosed with AKI and providers who take care of these patients followed by integration of the results into modification of an existing educational tool previously used in adult patients. The study will take place in three parts with the first involving interviews, the second involving tool modification and usability testing, and the third involving pilot testing of the tool's impact.

Eligibility criteria: Inclusion Criteria:

* age 1 to 18 years
* patients with diagnosis of AKI while hospitalized

Exclusion Criteria:

* legal blindness of deafness
* cognitive impairment that limits ability to consent
* non-English speaking
* patient age greater than age 18 years, 11 months

Primary outcomes:
measure: Acute Kidney Injury (AKI) Knowledge Assessment score
timeFrame: Baseline, 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Clarissa J Diamantidis, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Duke University
name: Rasheed Gbadegesin, MD
role: PRINCIPAL_INVESTIGATOR
References: